Research: How long should CAR-T patients be monitored?

Comparison of 15- Vs. 30-Day RPM for Outpatient CAR-T-Cell Therapy Across a Large Health System

Sarah Cannon, the Cancer Institute of HCA Healthcare, and Best Buy Health recently presented new research findings on the effectiveness of remote patient monitoring (RPM) for outpatient CAR-T therapy.

The research, presented at the ASH Annual Meeting, compares clinical outcomes and adherence for 15-day versus 30-day RPM schedules in outpatient chimeric antigen receptor T-cell therapy (CAR-T) patients.

View the poster to learn how the research demonstrates that an outpatient RPM program for patients undergoing CAR-T-cell therapy is safe, shows high patient adherence, and proposes an optimal period of monitoring that balances safety, efficiency, and patient experience.

Please fill out the form to access this content.

First Name*

Last Name*

Email address*

Phone*

Organization Name*

Job Title*

Organization Type*

Business Location*

CAPTCHA

Phone

This field is for validation purposes and should be left unchanged.

Category: Studies

Published On: December 13, 2024